Complete title: A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and young Adult Patients with Relapsed or Refractory Malignancies.
| Research Study Number | SC-4015 |
| Principal Investigator | Todd Cooper |
| Phase | I |
Other eligibility criteria may apply.
| Research Study Number | SC-4015 |
| Contact | Todd Cooper |
| Telephone | 206/987-2106 |
Keywords: Leukemia, Acute Myeloid (AML); Hematologic Malignancies; Leukemia; Lymphoma; Lymphoproliferative Disorders; Pediatric Cancers, Miscellaneous; Neuroblastoma; Lymphoma, Non-Hodgkin (NHL); Neuroectodermal Tumors, Primitive (PNET); Solid Tumors; Neoplasms, Germ Cell and Embryonal; Leukemia, Myeloid; Neoplasms; Leukemia, Lymphoid; Immunoproliferative Disorders; Lymphoma, B-Cell; Neuroectodermal Tumors; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Neoplasms, Neuroepithelial; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Immune System Diseases; Neuroectodermal Tumors, Primitive, Peripheral
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.